118 related articles for article (PubMed ID: 38833622)
1. Acute Endothelial Complications Post-Allogeneic Hematopoietic Cell Transplant in Patients with Pre-Cellular Therapy SARS-CoV-2 Infection.
Nimgaonkar I; Flaherty PW; Oshima MU; Hill JA
Clin Infect Dis; 2024 Jun; ():. PubMed ID: 38833622
[No Abstract] [Full Text] [Related]
2. Case Report: Favorable outcome of allogeneic hematopoietic stem cell transplantation in SARSCoV2 positive recipient, risk-benefit balance between infection and leukemia.
Oltolini C; Acerbis A; Orofino G; Racca S; Noviello M; Dispinseri S; Clementi N; Piemontese S; Xue E; Giglio F; Lupo Stanghellini MT; Diral E; Bruno A; Tassi E; Beretta V; Marzinotto I; Scarlatti G; Lampasona V; Ardemagni A; Sampaolo M; Bonini C; Corti C; Peccatori J; Castagna A; Ciceri F; Greco R
Front Immunol; 2023; 14():1184956. PubMed ID: 37287986
[TBL] [Abstract][Full Text] [Related]
3. Outcomes in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T Cell Therapy Recipients with Pre-Cellular Therapy SARS-CoV-2 Infection.
Nimgaonkar I; Yoke LH; Roychoudhury P; Flaherty PW; Oshima MU; Weixler A; Gauthier J; Greninger AL; Mielcarek M; Boeckh M; Liu C; Hill JA
Clin Infect Dis; 2024 Mar; ():. PubMed ID: 38427848
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study.
Hill JA; Martens MJ; Young JH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R; Peyton K; Shahid Z; Armistead P; Westervelt P; McCarty J; McGuirk J; Hamadani M; DeWolf S; Hosszu K; Sharon E; Spahn A; Toor AA; Waldvogel S; Greenberger LM; Auletta JJ; Horowitz MM; Riches ML; Perales MA
EClinicalMedicine; 2023 May; 59():101983. PubMed ID: 37128256
[TBL] [Abstract][Full Text] [Related]
5. Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study.
La Rosa C; Chiuppesi F; Park Y; Zhou Q; Yang D; Gendzekhadze K; Ly M; Li J; Kaltcheva T; Ortega Francisco S; Gutierrez MA; Ali H; Otoukesh S; Amanam I; Salhotra A; Pullarkat VA; Aldoss I; Rosenzweig M; Aribi AM; Stein AS; Marcucci G; Dadwal SS; Nakamura R; Forman SJ; Al Malki MM; Diamond DJ
Front Immunol; 2023; 14():1114131. PubMed ID: 36936918
[TBL] [Abstract][Full Text] [Related]
6. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 viral clearance during bone marrow aplasia after allogeneic hematopoietic stem cell transplantation-A case report.
Jarmoliński T; Matkowska-Kocjan A; Rosa M; Olejnik I; Gorczyńska E; Kałwak K; Ussowicz M
Pediatr Transplant; 2021 Aug; 25(5):e13875. PubMed ID: 32949079
[TBL] [Abstract][Full Text] [Related]
8. Humoral and Cellular Vaccination Responses against SARS-CoV-2 in Hematopoietic Stem Cell Transplant Recipients.
Lindemann M; Klisanin V; Thümmler L; Fisenkci N; Tsachakis-Mück N; Ditschkowski M; Schwarzkopf S; Klump H; Reinhardt HC; Horn PA; Koldehoff M
Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696183
[TBL] [Abstract][Full Text] [Related]
9. Antibody response to mRNA SARS-CoV-2 vaccination in 182 patients after allogeneic hematopoietic cell transplantation.
Beerlage A; Leuzinger K; Valore L; Mathew R; Junker T; Drexler B; Passweg JR; Hirsch HH; Halter J
Transpl Infect Dis; 2022 Jun; 24(3):e13828. PubMed ID: 35324045
[TBL] [Abstract][Full Text] [Related]
10. Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy.
Macková J; Hainz P; Kryštofová J; Roubalová K; Šťastná-Marková M; Vaníková Š; Musil J; Vydra J; Němečková Š
Leuk Res; 2023 Jul; 130():107314. PubMed ID: 37216792
[TBL] [Abstract][Full Text] [Related]
11. Is a third SARS-CoV-2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?
Spyridonidis A
Br J Haematol; 2023 Apr; 201(1):9-10. PubMed ID: 36477621
[TBL] [Abstract][Full Text] [Related]
12. Lessons learned from COVID-19 pandemic: outcomes after SARS-CoV-2 infection in hematopoietic cell transplant and cell therapy recipients.
Al-Ramahi JS; Shahzad M; Li K; DeJarnette S; Chaudhary SG; Lutfi F; Ahmed N; Balusu R; Bansal R; Abdelhakim H; Shune L; Singh AK; Abhyankar SH; McGuirk JP; Mushtaq MU
Leuk Lymphoma; 2023 Dec; 64(12):1981-1991. PubMed ID: 37574842
[TBL] [Abstract][Full Text] [Related]
13. Anti-SARS-CoV-2 vaccines in recipient and/or donor before allotransplant.
Jullien M; Coste-Burel M; Clemenceau B; Letailleur V; Guillaume T; Peterlin P; Garnier A; Bourgeois AL; Imbert BM; Ollier J; Grain A; Touzeau C; Moreau P; Béné MC; Vié H; Chevallier P
EJHaem; 2022 May; 3(2):484-487. PubMed ID: 35313664
[TBL] [Abstract][Full Text] [Related]
14. Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC.
Jondreville L; D'Aveni M; Labussière-Wallet H; Le Bourgeois A; Villate A; Berceanu A; Bezsera SM; Thiebaut A; Boissard-Simonet M; Legrand M; Cornillon J; Rubio MT; Chevallier P; Nguyen S
J Hematol Oncol; 2022 Nov; 15(1):169. PubMed ID: 36443846
[TBL] [Abstract][Full Text] [Related]
15. Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection.
Boussen I; Salmona M; Sicre De Fontbrune F; Xhaard A; De Castro N; Delaugerre C; Chaix ML; Molina JM
Antivir Ther; 2024 Feb; 29(1):13596535221097495. PubMed ID: 38353416
[TBL] [Abstract][Full Text] [Related]
16. Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature review.
Gopcsa L; Réti M; Andrikovics H; Bobek I; Bekő G; Bogyó J; Ceglédi A; Dobos K; Giba-Kiss L; Jankovics I; Kis O; Lakatos B; Mathiász D; Meggyesi N; Miskolczi G; Németh N; Paksi M; Riczu A; Sinkó J; Szabó B; Szilvási A; Szlávik J; Tasnády S; Reményi P; Vályi-Nagy I
Geroscience; 2024 Feb; 46(1):1083-1106. PubMed ID: 37414968
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic stem cell transplant in two pediatric patients testing positive for SARS-CoV-2: A case report.
Krajewski J; Chen J; Motiani J; Baer A; Appel B; Zakrzewski J; Hankewycz M; Durning N; Gillio A
Pediatr Transplant; 2022 Mar; 26(2):e14179. PubMed ID: 34708505
[TBL] [Abstract][Full Text] [Related]
18. Bronchiolitis obliterans syndrome following SARS-CoV-2 infection in an allogeneic hematopoietic stem cell recipient.
Bondeelle L; Giannotti F; Chalandon Y; Le Goff J; Tapparel C; Bergeron A
Am J Transplant; 2023 Jun; 23(6):844-847. PubMed ID: 36972802
[TBL] [Abstract][Full Text] [Related]
19. Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity.
Pourhassan H; La Rosa C; Chiuppesi F; Puing A; Aldoss I; Park Y; Zhou Q; Karpinski V; Faircloth K; Kaltcheva T; Johnson D; Francisco SO; Zaia JA; Nakamura R; Al Malki MM; Diamond DJ; Dadwal SS; Forman SJ
Blood Adv; 2022 Mar; 6(6):1645-1650. PubMed ID: 35008104
[TBL] [Abstract][Full Text] [Related]
20. Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients.
Kimura M; Ferreira VH; Kothari S; Pasic I; Mattsson JI; Kulasingam V; Humar A; Mah A; Delisle JS; Ierullo M; Majchrzak-Kita B; Kumar D; Hosseini-Moghaddam SM
Transplant Cell Ther; 2022 Oct; 28(10):706.e1-706.e10. PubMed ID: 35914727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
